#USA #Salt Lake City #XPRIZE #Healthy Aging #Healthspan

XPRIZE Healthspan Competition: A New Frontier in Healthy Aging

In a groundbreaking initiative aimed at revolutionizing healthy aging, XPRIZE has announced that ten finalist teams will receive $1 million each as part of the Healthspan competition's Milestone 2 Awards. This global effort, backed by a staggering $101 million prize pool, aims to tackle one of humanity's most critical challenges: extending not just the lifespan but the healthspan of individuals, allowing them to live healthier, more independent lives well into their later years.

The Competition’s Genesis

Launched in November 2023, the XPRIZE Healthspan competition focuses on proactive and accessible therapies that specifically target the biology of aging. Over seven years, it seeks to accelerate the development and clinical testing of innovative treatments that can potentially restore muscle, cognitive functions, and immune response in adults aged between 50 to 90 by a minimum of ten years — with an audacious goal of twenty years — within a single year of treatment.

This competition is unique as it represents the first concerted health-focused competition of its kind, encouraging bold scientific approaches to address aging-related issues. Furthermore, an additional $10 million incentive has been earmarked to reward breakthroughs in treating Facioscapulohumeral Muscular Dystrophy (FSHD), demonstrating XPRIZE's commitment to advancing muscle health.

Celebrating the Finalists

The award ceremony, held recently in Salt Lake City, recognized the contributions of several innovative teams from four countries: the United States, South Korea, Japan, and China. The ten teams were chosen based on their scientific rigor, approach scalability, and readiness to enter the clinical trial phase. The following are the honored finalists:
1. AgelessRx (USA)
2. Goda Lab (University of Tokyo, Japan)
3. Johns Hopkins-Suninflam (USA)
4. Longeveron, Inc. (USA)
5. Minicircle Inc. (USA)
6. Mitochondrial All Stars (USA)
7. NYC-Vita Trial (Mount Sinai Health System, USA)
8. RETRO-EPIGERNA (Macau University, China)
9. RPRGAON-Progeria (South Korea)
10. TIME TRAVELER – Plant-EVs (Japan)

Each awardee will not only receive funding but also gain access to critical clinical testing resources, bringing total investment for these initial milestones to $10 million, all geared towards expediting the development of their therapeutic strategies.

Diverse Approaches to Healthy Aging

The strategies employed by these teams represent an impressive range of innovative solutions targeting aspects of aging. From new and existing drugs that focus on metabolism and inflammation to first-of-its-kind medications that repair cellular mitochondria—often referred to as the body’s energy batteries—these finalists showcase the potential for transformative advancements in healthspan science. Other highlighted approaches include:

• - Biologic treatments aimed at reducing cell damage and inflammation.
• - Stem cell therapies utilizing patients' own cells to enhance mitochondrial function and general cellular health.
• - Techniques for delivering temporary genetic instructions to produce therapeutic proteins, which support cell growth and energy metabolism.
• - Novel food-derived therapies and personalized telehealth interventions that leverage AI for optimized prescriptions.

As these finalists advance into the next stage of the competition, they will further refine their therapies, focusing on scalable solutions that extend beyond traditional drug applications to include supplements and dietary approaches that can support healthy aging.

Looking Forward: The Next Steps

From 2026 to 2029, the finalists will engage in rigorous clinical trials, each lasting up to a year, to validate their therapeutic solutions. Managed by the University of Utah's Data Coordinating Center and in collaboration with leading research institutes, this phase is crucial for generating the evidence necessary to solidify the status of these treatments in the medical landscape.

The culmination of this competition will occur in 2030, with XPRIZE offering a grand prize of up to $81 million for the most groundbreaking scientific breakthrough in healthspan enhancement. This will not only mark a significant milestone in aging health but could also redefine how society addresses longevity and the quality of life in older age.

Conclusion

As the global population ages, the importance of innovative approaches to extend both lifespan and healthspan grows more pressing. XPRIZE Healthspan stands as a beacon of hope, uniting scientists and innovators in the common goal of redefining aging for future generations. With the financial backing and strategic support from organizations like Hevolution Foundation and GSK, this initiative is primed to accelerate advancements that can profoundly impact public health and individual well-being.